74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis

INTRODUCTION: The objective was to describe the prevalence, types, and predictors of adverse events (AEs) in rheumatoid arthritis (RA) patients treated with infliximab and methotrexate in a daily clinical setting. METHODS: This was a prospective, multi-center, open-label, 74-week observational study...

Descripción completa

Detalles Bibliográficos
Autores principales: Delabaye, Isabelle, De Keyser, Filip
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2911915/
https://www.ncbi.nlm.nih.gov/pubmed/20569501
http://dx.doi.org/10.1186/ar3058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2911915/
https://www.ncbi.nlm.nih.gov/pubmed/20569501
http://dx.doi.org/10.1186/ar3058

Ejemplares similares